CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2020		$ 35	$ 320,280	$ (347,352)	$ (27,037)
Beginning balance (in shares) at Dec. 31, 2020	[1]	34,765,280
Issuance of common stock, net of issuance cost		$ 9	37,616		37,625
Issuance of common stock, net of issuance cost (in shares)	[1]	8,749,999
Issuance of common stock under the Sales Agreement, net		$ 2	8,573		8,575
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	1,867,552
Share-based compensation related to stock options			1,176		1,176
Share-based compensation related to restricted stock awards			781		781
Exercise of warrants (in shares)	[1]	173,816
Reacquisition of equity component of convertible notes			(12,019)		(12,019)
Equity component of convertible notes, net of transaction costs			12,027		12,027
Net loss for the period				(20,915)	(20,915)
Ending balance at Sep. 30, 2021		$ 46	368,434	(368,267)	213
Ending balance (in shares) at Sep. 30, 2021	[1]	45,556,647
Beginning balance at Jun. 30, 2021		$ 46	367,863	(364,068)	3,841
Beginning balance (in shares) at Jun. 30, 2021	[1]	45,556,647
Share-based compensation related to stock options			344		344
Share-based compensation related to restricted stock awards			219		219
Reacquisition of equity component of convertible notes			(12,019)		(12,019)
Equity component of convertible notes, net of transaction costs			12,027		12,027
Net loss for the period				(4,199)	(4,199)
Ending balance at Sep. 30, 2021		$ 46	368,434	(368,267)	213
Ending balance (in shares) at Sep. 30, 2021	[1]	45,556,647
Beginning balance at Dec. 31, 2021		$ 46	368,852	(374,934)	(6,036)
Beginning balance (in shares) at Dec. 31, 2021	[1]	45,556,647
Issuance of common stock under the Sales Agreement, net		$ 4	4,157		4,161
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	3,841,479
Share-based compensation related to stock options			592		592
Share-based compensation related to restricted stock awards			954		954
Share-based compensation related to restricted stock awards (in shares)	[1]	759,482
Exercise of warrants			2		2
Exercise of warrants (in shares)	[1]	1,000
Net loss for the period				(11,187)	(11,187)
Ending balance at Sep. 30, 2022		$ 50	374,557	(386,121)	(11,514)
Ending balance (in shares) at Sep. 30, 2022	[1]	50,158,608
Beginning balance at Jun. 30, 2022		$ 49	372,616	(382,554)	(9,889)
Beginning balance (in shares) at Jun. 30, 2022	[1]	48,712,952
Issuance of common stock under the Sales Agreement, net		$ 1	1,519		1,520
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	1,445,656
Share-based compensation related to stock options			298		298
Share-based compensation related to restricted stock awards			124		124
Net loss for the period				(3,567)	(3,567)
Ending balance at Sep. 30, 2022		$ 50	$ 374,557	$ (386,121)	$ (11,514)
Ending balance (in shares) at Sep. 30, 2022	[1]	50,158,608

[1] Common stock, $0.001 par value; Authorized – as of September 30, 2022 and 2021 – 144,000,000 and 120,000,000 shares, respectively.